STAT News published “The Placebo Response: A Hidden Risk to COVID-19 Trials” written by Tools4Patient authors on October 13, 2020. The article, authored by Erica Smith PhD, VP of Business Development and Dominique Demolle PhD, CEO, was published in STAT’s First Opinion column. The article asserts that the success of the abundant drug development program for COVID-19 therapies
The search for drugs to treat and prevent SARS-CoV-2 infection is ongoing, with more than 1200 drugs in the pipeline and more 3,200 clinical trials planned or initiated as of 21 September 2020 (GlobalData). The success of these studies, however, may be at risk due to an invisible threat – the placebo response.
Learn the importance of considering patient psychological traits, expectations, perception of patient relationship with the trial physician and staff, and social structure in efforts to understand the impact of the COVID-19 pandemic on clinical trials.
Osteoarthritis (OA) is common musculoskeletal disease with increased incidence and prevalence associated with aging. It affects around 10 % of the population and is 10 times more common than rheumatoid arthritis (RA).
A recent study published in Nature Human Behavior developed a methodology to understand and assess the role of physician expectation on the placebo response. Read more about this study here.
Erica Smith, VP of Business Development, speaks with Daniel Levin of The Bio Report Podcast about the Placebell©™ method to reduce the impact of the placeb response in drug development”.